Pharsight

Promacta Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6280959 NOVARTIS Metal complexes
Oct, 2018

(5 years ago)

US7473686 NOVARTIS Thrombopoietin mimetics
May, 2021

(3 years ago)

US7452874 NOVARTIS Thrombopoietin mimetics
May, 2021

(3 years ago)

US7160870 NOVARTIS Thrombopoietin mimetics
Nov, 2022

(1 year, 6 months ago)

US7547719 NOVARTIS 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine)
Jul, 2025

(1 year, 29 days from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6280959

(Pediatric)

NOVARTIS Metal complexes
Apr, 2019

(5 years ago)

US7332481 NOVARTIS Thrombopoietin mimetics
May, 2021

(3 years ago)

US7790704 NOVARTIS Thrombopoietin mimetics
May, 2021

(3 years ago)

US7452874

(Pediatric)

NOVARTIS Thrombopoietin mimetics
Nov, 2021

(2 years ago)

US7790704

(Pediatric)

NOVARTIS Thrombopoietin mimetics
Nov, 2021

(2 years ago)

US7332481

(Pediatric)

NOVARTIS Thrombopoietin mimetics
Nov, 2021

(2 years ago)

US7473686

(Pediatric)

NOVARTIS Thrombopoietin mimetics
Nov, 2021

(2 years ago)

US7160870

(Pediatric)

NOVARTIS Thrombopoietin mimetics
May, 2023

(1 year, 25 days ago)

US7795293 NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
May, 2023

(1 year, 24 days ago)

US7795293

(Pediatric)

NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Nov, 2023

(6 months ago)

US7547719

(Pediatric)

NOVARTIS 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine)
Jan, 2026

(1 year, 6 months from now)

Promacta Kit is owned by Novartis.

Promacta Kit contains Eltrombopag Olamine.

Promacta Kit has a total of 16 drug patents out of which 14 drug patents have expired.

Expired drug patents of Promacta Kit are:

  • US6280959*PED
  • US7332481
  • US7790704
  • US7452874*PED
  • US7790704*PED
  • US7332481*PED
  • US7473686*PED
  • US7160870*PED
  • US7795293
  • US7795293*PED
  • US6280959
  • US7473686
  • US7452874
  • US7160870

Promacta Kit was authorised for market use on 27 September, 2018.

Promacta Kit is available in for suspension;oral dosage forms.

Promacta Kit can be used as treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp), treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy.

The generics of Promacta Kit are possible to be released after 13 January, 2026.

Drug Exclusivity Drug Exclusivity Expiration
ODE*(ODE*) Nov 16, 2025
New Dosing Schedule(D-149) Jun 11, 2018
New Indication(I-711) Jun 11, 2018
Orphan Drug Exclusivity(ODE) Aug 26, 2021
Pediatric Exclusivity(PED) Feb 26, 2022
Orphan Drug Exclusivity(ODE-74) Aug 26, 2021

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using ELTROMBOPAG OLAMINE ingredient

Market Authorisation Date:

27 September, 2018

Treatment:

Treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy; Treatment of thrombocytopenia in adult and pediatric patients 1 ...

Dosage:

FOR SUSPENSION;ORAL

How can I launch a generic of PROMACTA KIT before its drug patent expiration?

More Information on Dosage

PROMACTA KIT family patents

Family Patents